Mga Batayang Estadistika
| CIK | 1786511 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fresh2 Group Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| April 17, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39137 Fresh2 Group Limited 880 3RD AVE FL 7 NEW YORK, NY 10022-4730 United States (Address of principal executive office) Indicate by check mark whether the registra |
|
| April 2, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39137 Fresh2 Group Limited 880 3RD AVE FL 7 NEW YORK, NY 10022-4730 United States (Address of principal executive office) Indicate by check mark whether the registra |
|
| December 23, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39137 Fresh2 Group Limited 880 3RD AVE FL 7 NEW YORK, NY 10022-4730 United States (Address of principal executive office) Indicate by check mark whether the regis |
|
| November 14, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39137 Fresh2 Group Limited 880 3RD AVE FL 7 NEW YORK, NY 10022-4730 United States (Address of principal executive office) Indicate by check mark whether the regis |
|
| July 24, 2024 |
Exhibit 16.1 July 24, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Fresh2 Group Ltd. under its Form 6-K dated July 24, 2024. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other statements of Fresh2 Group Ltd. contained therein. Very truly you |
|
| July 24, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39137 Fresh2 Group Limited 880 3RD AVE FL 7 NEW YORK, NY 10022-4730 United States (Address of principal executive office) Indicate by check mark whether the registran |
|
| June 26, 2024 |
Fresh2 Group Limited Announces Plan to Implement ADS Ratio Change Exhibit 99.1 Fresh2 Group Limited Announces Plan to Implement ADS Ratio Change New York, NY, June 24, 2024 (GLOBE NEWSWIRE) - Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or “the Company”), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that it plans to change the ratio of its American depositary shares (“ADSs”) to its Class A ordinary s |
|
| June 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2024 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporation |
|
| June 24, 2024 |
Fresh2 Group Limited As of January 25, 2024 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Re: Fresh2 Group Limited – Convertible Notes Due June 6, 2025 Ladies & Gentlemen: We refer to the Deposit Agreement, dated as of February 3, 2020, by and among Fresh2 Group Limited (formerly known as “AnPac Bio-Medical Science Co., Ltd.”), a business company incorporated and ex |
|
| June 24, 2024 |
Fresh2 Group Limited 801 Bixing Street, Bihu County Lishui, Zhejiang Province, China, 323006 Fresh2 Group Limited 801 Bixing Street, Bihu County Lishui, Zhejiang Province, China, 323006 As of May 22, 2023 Citibank, N. |
|
| June 24, 2024 |
ANPAC BIO-MEDICAL SCIENCE CO., LTD. and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF FEBRUARY 3, 2020 Amendment No. 1 to the Deposit Agreement Dated as of November 4, 2022 Table of Contents Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Effective Date 2 ARTICL |
|
| June 24, 2024 |
Fresh2 Group Limited and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF FEBRUARY 3, 2020 Amendment No. 2 to the Deposit Agreement Dated as of [l], 2024 Table of Contents Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Effective Date 2 ARTICLE II AMENDMENTS TO DEP |
|
| June 24, 2024 |
As filed with the Securities and Exchange Commission on June 24, 2024 Registration No. |
|
| June 24, 2024 |
[Remaining of this page intentionally left in blank] As of September 29, 2023 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Re: Fresh2 Group Limited – Convertible Notes Due March 22, 2025 Ladies & Gentlemen: We refer to the Deposit Agreement, dated as of February 3, 2020, by and among Fresh2 Group Limited (formerly known as “AnPac Bio-Medical Science Co., Ltd.”), a company organized and existing under the laws of the |
|
| June 24, 2024 |
Fresh2 Group Limited As of January 25, 2024 Citibank, N.A. – ADR Depositary 388 Greenwich Street New York, New York 10013 Re: Warrant Exercise Letter Agreement (the “Letter Agreement”) Ladies & Gentlemen, We refer to the Deposit Agreement, dated as of February 3, 2020, by and among Fresh2 Group Limited (formerly known as “AnPac Bio-Medical Science Co., Ltd.”), a business company incorporated and e |
|
| June 24, 2024 |
Fresh2 Group Limited As of January 25, 2024 Citibank, N.A. – ADR Depositary 388 Greenwich Street New York, New York 10013 Re: Warrant Exercise Letter Agreement (the “Letter Agreement”) Ladies & Gentlemen, We refer to the Deposit Agreement, dated as of February 3, 2020, by and among Fresh2 Group Limited (formerly known as “AnPac Bio-Medical Science Co., Ltd.”), a business company incorporated and e |
|
| May 23, 2024 |
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq Exhibit 99.1 Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq New York, NY, May 23, 2024 (GLOBE NEWSWIRE) - Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or the “Company”), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that on May 23, 2024, it received a delinquency compliance alert notice from the |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporation) |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporatio |
|
| April 22, 2024 |
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq Exhibit 99.1 Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq New York, NY, April 22, 2024 (GLOBE NEWSWIRE) - Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or the “Company”), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that on April 18, 2024, it received a delinquency compliance alert notice from |
|
| April 2, 2024 |
SEC FILE NUMBER: 001-39137 CUSIP NUMBER: 03635R206 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Fresh2 Group Limited (Exact name of Company as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporation) |
|
| April 2, 2024 |
Fresh2 Group Limited 650 5TH AVE, STE 2416 NEW YORK, NY 10019-6108, United States Exhibit 10.2 Fresh2 Group Limited 650 5TH AVE, STE 2416 NEW YORK, NY 10019-6108, United States March 27, 2024 JAK Opportunities V LLC 17 State Street, 2100 New York, New York 10004 Re: Warrant Dear Sirs and Madams: Reference is made to that certain (i) Series C Warrant, dated September 25, 2023, (ii) Series D Warrant, dated September 25, 2023, (iii) Series C Warrant, dated December 6, 2023, and (i |
|
| April 2, 2024 |
FRESH2 GROUP LIMITED Convertible Note Exhibit 10.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 27, 2024 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT between YBB TECHNOLOGY INC. and Fresh2 Information Inc dated as of March 22, 2024 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”), dated as of March 22, 2024, is entered into between YBB TECHNOLOGY INC., a New Jersey corporation (“Seller”), Fresh2 Group Limited, an exempted company with limited liability incorporated under the laws of |
|
| March 25, 2024 |
March 25, 2024 Juan Grana Lauren Nguyen Division of Corporation Finance Office of Industrial Applications and Services U. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 2) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number: 001-39137 OR ☐ TRANSITION REPO |
|
| March 25, 2024 |
Exhibit 10.1 SALARY CONVERSION AGREEMENT THIS SALARY CONVERSION AGREEMENT (the “Agreement”) is entered into as of March , 2024, by and between Fresh2 Group Limited (“Fresh2”) and [*] (“Employee”). Fresh2 and Employee may be referred to herein individually as a “Party” and collectively as the “Parties.” Recitals: WHEREAS, the Employee and [an affiliate of Fresh2] (“Company”) entered into an employm |
|
| March 25, 2024 |
Independent Registered Public Accounting Firm’s Consent Exhibit 15.1 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in this Registration Statement of Fresh2 Group Limited (f/k/a AnPac Bio-Medical Science Co., Ltd.) on Form S-8 (File No.333-274821, No.333-265413 and No.333-259748) and Form F-3 (File No.333-256630) of our report dated May 16, 2022, which includes an explanatory paragraph as to the Com |
|
| March 25, 2024 |
Exhibit 10.5 SHARES PURCHASE AGREEMENT SHARES PURCHASE AGREEMENT (this “Agreement”), dated as of February 20, 2024, by and between Fresh2 Group Limited, a British Virgin Islands corporation (the “Company”), and Hong Qin (the “Investor”). A. The Company wishes to sell to the Investor, and the Investor wishes to purchase, on the terms and subject to the conditions set forth in this Agreement, ordina |
|
| March 25, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Haohan Xu, certify that: 1. I have reviewed this annual report on Form 20-F/A of Fresh2 Group Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| March 25, 2024 |
AMENDMENT TO SHARE PURCHASE AGREEMENT Exhibit 10.3 AMENDMENT TO SHARE PURCHASE AGREEMENT Amendment to the Share Purchase Agreement, dated as of February 20, 2024 (this “Amendment”), is entered into by and among Fresh2 Group Limited (the “Company”), and Applegreen LLC (the “Investor”) (each a “Party” and together with the Company, the “Parties”). WHEREAS, the Company and Investor have entered into that certain share purchase agreement |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporat |
|
| March 25, 2024 |
Independent Registered Public Accounting Firm’s Consent Exhibit 15.2 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in this Registration Statement of Fresh2 Group Limited (f/k/a AnPac Bio-Medical Science Co., Ltd.) on Form S-8 (File No.333-274821, No.333-265413 and No.333-259748) and Form F-3 (File No.333-256630) of our report dated May 16, 2023, which includes an explanatory paragraph as to the Com |
|
| March 25, 2024 |
Exhibit 10.2 DEBT CONVERSION AGREEMENT THIS DEBT CONVERSION AGREEMENT (the “Agreement”) is entered into as of March 19, 2024, by and between Fresh2 Group Limited (“Fresh2”) and Shouli Zhang (“Creditor”). Fresh2 and Creditor may be referred to herein individually as a “Party” and collectively as the “Parties.” Recitals: WHEREAS, the Creditor and an affiliate of Fresh2 (“Company”) entered into a Deb |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 25, 2024 |
Exhibit 10.4 SUPPLEMENTAL AGREEMENT This supplemental agreement (the “Supplemental Agreement”) is made and entered into as of February 20, 2024 (the “Effective Date”), between Fresh2 Group Limited (formerly, “AnPac Bio-Medical Science Co., Ltd.”) (the “Company”), and Applegreen LLC (the “Investor”) (Each, “Party”, or collectively, “Parties”). WHEREAS, the Parties entered into that certain Share Pu |
|
| March 25, 2024 |
Exhibit 16.1 March 25, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Fresh2 Group Limited (formerly known as AnPac Bio-Medical Science Co., Ltd.) under Item 16F of its Amendment No. 2 to Form 20-F dated March 22, 2024. We agree with the statements concerning our Firm in such Amendment No. 2 to Form 20-F; we are no |
|
| March 25, 2024 |
Exhibit 10.6 SHARES PURCHASE AGREEMENT SHARES PURCHASE AGREEMENT (this “Agreement”), dated as of February 20, 2024, by and between Fresh2 Group Limited, a British Virgin Islands corporation (the “Company”), and Danni Zhang (the “Investor”). A. The Company wishes to sell to the Investor, and the Investor wishes to purchase, on the terms and subject to the conditions set forth in this Agreement, ord |
|
| March 25, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Xiaoyu Li, certify that: 1. I have reviewed this annual report on Form 20-F/A of Fresh2 Group Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| March 25, 2024 |
Exhibit 10.2 SUPPLEMENTAL AGREEMENT This supplemental agreement (the “Supplemental Agreement”) is made and entered into as of [*] (the “Effective Date”), between Fresh2 Group Limited (the “Company”), and ***INC (the “Investor”) (Each, “Party”, or collectively, “Parties”). WHEREAS, the Parties entered into that certain Share Purchase Agreement dated as of [*] (the “Purchase Agreement”); WHEREAS, th |
|
| March 25, 2024 |
AMENDMENT TO SHARE PURCHASE AGREEMENT Exhibit 10.1 AMENDMENT TO SHARE PURCHASE AGREEMENT Amendment to the Share Purchase Agreement, dated as of [*], 2024 (this “Amendment”), is entered into by and among Fresh2 Group Limited (the “Company”), and [*] (the “Investor”) (each a “Party” and together with the Company, the “Parties”). WHEREAS, the Company and Investor have entered into that certain share purchase agreement (the “Share Purchas |
|
| February 16, 2024 |
Fresh2 Group Limited 650 5TH AVE, STE 2416 NEW YORK, NY 10019-6108, United States Exhibit 4.1 Fresh2 Group Limited 650 5TH AVE, STE 2416 NEW YORK, NY 10019-6108, United States February 15, 2024 JAK Opportunities V LLC 17 State Street, 2100 New York, New York 10004 Re: Note Dear Sirs and Madams: Reference is made to that certain convertible promissory note dated September 25, 2023 issued by Fresh2 Group Limited, a company organized under the laws of the British Virgin Islands, ( |
|
| February 16, 2024 |
Fresh2 Group Limited 650 5TH AVE, STE 2416 NEW YORK, NY 10019-6108, United States Exhibit 4.2 Fresh2 Group Limited 650 5TH AVE, STE 2416 NEW YORK, NY 10019-6108, United States February 15, 2024 JAK Opportunities V LLC 17 State Street, 2100 New York, New York 10004 Re: Note Dear Sirs and Madams: Reference is made to that certain convertible promissory note dated December 6, 2023 issued by Fresh2 Group Limited, a company organized under the laws of the British Virgin Islands, (th |
|
| February 16, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorpora |
|
| February 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporat |
|
| February 1, 2024 |
Fresh2 Group Ltd. Announces Receipt of a Bid Deficiency Notice from Nasdaq Exhibit 99.1 Fresh2 Group Ltd. Announces Receipt of a Bid Deficiency Notice from Nasdaq New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) - Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or “the Company”), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that on January 26, 2024, it received a deficiency notice (the “Notice”) from The Nasdaq Stoc |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2023 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorpora |
|
| January 29, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 Fresh2 Group Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-39137 Not Applicable (State or other jurisdiction of incorporat |
|
| January 29, 2024 |
Fresh2 Group Ltd. Announces Acquisition of Cross-Border Food E-Commerce Platform Youfood Group Inc. Exhibit 99.1 Fresh2 Group Ltd. Announces Acquisition of Cross-Border Food E-Commerce Platform Youfood Group Inc. New York, NY, January 4, 2024/PRNewswire/ - Fresh2 Group Ltd. (NASDAQ: FRES) ("Fresh2" or "the Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that it has, through its subsidiary Fresh2 Technology Inc., signed a de |
|
| January 29, 2024 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of December 10, 2023 by and among (1) Fresh2 Group Limited, an exempted company with limited liability incorporated under the laws of the British Virgin Islands (the “Fresh2”); (2) Xiaofan Lin and Shengren Yan as the selling shareholders of Youfood Group Inc (each, “Seller”, collective |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number: 001-39137 OR ☐ TRANSITION REPO |
|
| January 9, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Xiaoyu Li, certify that: 1. I have reviewed this annual report on Form 20-F/A of Fresh2 Group Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| January 9, 2024 |
Independent Registered Public Accounting Firm’s Consent Exhibit 15.2 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in this Registration Statement of Fresh2 Group Limited (f/k/a AnPac Bio-Medical Science Co., Ltd.) on Form S-8 (File No.333-274821, No.333-265413 and No.333-259748) and Form F-3 (File No.333-256630) of our report dated May 16, 2023, which includes an explanatory paragraph as to the Com |
|
| January 9, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Haohan Xu, certify that: 1. I have reviewed this annual report on Form 20-F/A of Fresh2 Group Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| January 9, 2024 |
January 9, 2024 Juan Grana Lauren Nguyen Division of Corporation Finance Office of Industrial Applications and Services U. |
|
| January 9, 2024 |
Exhibit 16.1 January 9, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Fresh2 Group Limited (formerly known as AnPac Bio-Medical Science Co., Ltd.) under Item 16F of its Amendment No. 1 to Form 20-F dated January 9, 2024. We agree with the statements concerning our Firm in such Amendment No. 1 to Form 20-F; we are |
|
| January 9, 2024 |
Independent Registered Public Accounting Firm’s Consent Exhibit 15.1 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in this Registration Statement of Fresh2 Group Limited (f/k/a AnPac Bio-Medical Science Co., Ltd.) on Form S-8 (File No.333-274821, No.333-265413 and No.333-259748) and Form F-3 (File No.333-256630) of our report dated May 16, 2022, which includes an explanatory paragraph as to the Com |
|
| December 15, 2023 |
Appointment of New Independent Director Exhibit 99.1 Appointment of New Independent Director New York, NY, December 15, 2023/PRNewswire/ - Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or “the Company”), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced the appointment of Zhijun (Michael) Liang, as an independent director of the Company, effective January 1, 2024. Zhijun (Michael) |
|
| December 15, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the r |
|
| December 6, 2023 |
FRESH2 GROUP LIMITED Series D Warrant To Purchase Ordinary Shares Exhibit 10.5 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| December 6, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-256630 PROSPECTUS SUPPLEMENT (To Prospectus dated June 7, 2021) FRESH2 GROUP LIMITED $500,000 Convertible Notes Series C Warrants to Purchase 322,581 American Depositary Shares (ADSs) Series D Warrants to Purchase 354,610 ADSs Up to 322,581 ADSs issuable upon conversion of the $500,000 Convertible Notes Up to 91,888 ADSs issuable in lieu of pay |
|
| December 6, 2023 |
FRESH2 GROUP LIMITED Series C Warrant To Purchase Ordinary Shares Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| December 6, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the r |
|
| December 6, 2023 |
FRESH2 GROUP LIMITED Convertible Note Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| December 6, 2023 |
AMENDMENT to Securities Purchase Agreement Exhibit 10.2 AMENDMENT to Securities Purchase Agreement This Amendment to Securities Purchase Agreement (this “Agreement”) is made and entered into as of December 6, 2023, by and among Fresh2 Group Limited, a company organized under the laws of the British Virgin Islands, with offices located at 650 5TH AVE STE 2416, NEW YORK, NY 10019-6108, United States (the “Company”), JAK OPPORTUNITIES V LLC ( |
|
| December 4, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the |
|
| December 4, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed financial statements are based upon the historical financial statements of FRESH2 GROUP LIMITED, formerly ANPAC BIO-MEDICAL SCIENCE CO., LTD. (the “Company” or “Fresh2”), adjusted to give effect to the acquisition of 98.64% of the issued and outstanding securities Roxe Holding Inc. |
|
| December 4, 2023 |
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS A Operating Results The following discussion and analysis of our financial condition as of June 30, 2023 and results of operations for the six months ended June 30, 2023 and June 30, 2022 should be read together with our condensed interim consolidated financial statements and related notes included e |
|
| December 4, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 (Address of principal executive office) Indicate by check mark whether the registr |
|
| December 4, 2023 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 4, 2023 by and among (1) Fresh2 Group Limited, an exempted company with limited liability incorporated under the laws of the British Virgin Islands (the “Fresh2”); (2) Vertical Channel Limited, Zero2First Capital Limited, and Future Capital Tech Pte. Ltd, as the selling sh |
|
| December 4, 2023 |
FRESH2 GROUP LIMITED INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 FRESH2 GROUP LIMITED INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Financial Statements F-1 Unaudited Condensed Consolidated Balance Sheets as of December 31, 2022 and June 30, 2023 F-2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023 F-3 Unaudited Condense |
|
| December 4, 2023 |
ROXE HOLDING INC UNAUDITED CONSOLIDATED COMBINED BALANCE SHEET Exhibit 99.2 ROXE HOLDING INC UNAUDITED CONSOLIDATED COMBINED BALANCE SHEET June 30, 2023 Unaudited December 31, 2022 Audited Assets Current assets Cash and cash equivalents 8,416 7,694 Accounts receivables, net 52,277 52,277 Prepaid expenses - 51,767 Other receivables 86,659 108,849 Total Current assets 147,351 220,587 Digital Assets 6,121 8,410 Property and equipment, net 6,063 1,846 Intangible |
|
| November 9, 2023 |
FRESH2 GROUP LIMITED INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 FRESH2 GROUP LIMITED INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Financial Statements F-1 Unaudited Condensed Consolidated Balance Sheets as of December 31, 2022 and June 30, 2023 F-2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023 F-3 Unaudited Condense |
|
| November 9, 2023 |
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS A Operating Results The following discussion and analysis of our financial condition as of June 30, 2023 and results of operations for the six months ended June 30, 2023 and June 30, 2022 should be read together with our condensed interim consolidated financial statements and related notes included e |
|
| November 9, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the r |
|
| October 2, 2023 |
Exhibit 10.1 ANPAC BIO-MEDICAL SCIENCE CO., LTD. 2022 SHARE INCENTIVE PLAN 2 Adopted on August 28, 2022 (the “Effective Date”) The purpose of the Amended and Restatement 2022 Share Incentive Plan 2 (the “Plan”) is to promote the interests of AnPac Bio-Medical Science Co., Ltd. (the “Company”) and its shareholders by providing grantees with an appropriate incentive to encourage them to continue con |
|
| October 2, 2023 |
FRESH2 GROUP LIMITED 2023 SHARE INCENTIVE PLAN Adopted on August 23 , 2023 (the “Effective Date”) Exhibit 10.2 FRESH2 GROUP LIMITED 2023 SHARE INCENTIVE PLAN Adopted on August 23 , 2023 (the “Effective Date”) The purpose of the Amended and Restatement 2023 Share Incentive Plan (the “Plan”) is to promote the success and enhance the value of FRESH2 GROUP LIMITED, an exempted company incorporated under the laws of the BVI (the “Company”), by linking the personal interests of the Directors, Employ |
|
| October 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Fresh2 Group Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Registration Fee Title of Securities To Be Registered (1) Amount to be Registered (2) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Class A ordinary shares, par value $0. |
|
| October 2, 2023 |
As filed with the Securities and Exchange Commission on October 2, 2023 As filed with the Securities and Exchange Commission on October 2, 2023 Registration No. |
|
| September 25, 2023 |
FRESH2 GROUP LIMITED Convertible Note Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| September 25, 2023 |
FRESH2 GROUP LIMITED Series C Warrant To Purchase Ordinary Shares Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| September 25, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-256630 PROSPECTUS SUPPLEMENT (To Prospectus dated June 7, 2021) FRESH2 GROUP LIMITED $400,000 Convertible Notes Series C Warrants to Purchase 258,065 American Depositary Shares (ADSs) Series D Warrants to Purchase 283,688 ADSs Up to 258,065 ADSs issuable upon conversion of the $400,000 Convertible Notes Up to 73,510 ADSs issuable in lieu of pay |
|
| September 25, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 22, 2023, is by and among Fresh2 Group Limited, a company organized under the laws of the British Virgin Islands, with offices located at 650 5TH AVE STE 2416, NEW YORK, NY 10019-6108, United States (the “Company”), and each of the investors listed on the Schedule of Buyers attach |
|
| September 25, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the |
|
| September 25, 2023 |
FRESH2 GROUP LIMITED Series D Warrant To Purchase Ordinary Shares Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| September 12, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 (Address of principal executive office) Indicate by check mark whether the regist |
|
| September 12, 2023 |
Exhibit 99.1 FRESH2 GROUP LIMITED (FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.) UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS The following unaudited pro forma condensed financial statements are based upon the historical financial statements of FRESH2 GROUP LIMITED, formerly ANPAC BIO-MEDICAL SCIENCE CO., LTD. (the “Company”), adjusted to give effect to the sale of its business of providing |
|
| August 28, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the reg |
|
| August 21, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On July 17, 2023, Fresh2 entered into a share purchase agreement (the “Purchase Agreement”) with Roxe. Pursuant to the Purchase Agreement, subject to the satisfaction of the conditions to closing, including approval by the Fresh2 stockholders pursuant to the rules of the Nasdaq Stock Market, Fresh2 acquired 51% of the issued |
|
| August 21, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 (Address of principal executive office) Indicate by check mark whether the registran |
|
| August 21, 2023 |
ROXE HOLDING INC. Index to Financial Statements Exhibit 99.2 ROXE HOLDING INC. Index to Financial Statements Report of Independent Registered Public Accounting Firm 1-2 Consolidated Balance Sheets as of December 31, 2022, and 2021 3-6 Notes to the Financial Statements 7-23 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Roxe Holding Inc. Opinions on the Financial Statements We have audit |
|
| August 15, 2023 |
Exhibit 10.3 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of July 28, 2023 (“Effective Date”) by and among (1) Fresh2 Group Limited, an exempted company with limited liability incorporated under the laws of the British Virgin Islands (the “Seller”); (3) Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. (昌和生物医学科技（扬州）有限公司) (the “Company”); an |
|
| August 15, 2023 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of July 28, 2023 (“Effective Date”) by and among (1) Fresh2 Group Limited, an exempted company with limited liability incorporated under the laws of the British Virgin Islands (the “Seller”); (3) AnPac Bio-Medical Technology (Lishui) Co., Ltd. (安派科生物医学科技（丽水）有限公司) (the “Company”); and ( |
|
| August 15, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 (Address of principal executive office) Indicate by check mark whether the registran |
|
| August 15, 2023 |
Exhibit 10.2 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of July 28, 2023 by and among (1) Fresh2 Group Limited, an exempted company with limited liability incorporated under the laws of the British Virgin Islands (the “Seller”); (3) Anpac Technology USA CO., LTD. (the “Company”); and (4) New-Horizon Bio-Medical Science Co., Ltd. (the “Purch |
|
| July 28, 2023 |
Exhibit 99.1 Fresh2 Group Ltd. (FRES) Rings the Nasdaq Stock Market Opening Bell, Driving the Online Transformation of the Restaurant Industry NEW YORK, July 14, 2023 /PRNewswire/ - Fresh2 (Nasdaq: FRES), the innovative online B2B e-commerce marketplace, proudly showcased its commitment to transforming the restaurant industry at the highly anticipated Nasdaq Opening Bell Ceremony. The event marked |
|
| July 28, 2023 |
Fresh2 Group Ltd. Completes Acquisition of SpeedIn INC, a Delivery Service Provider Exhibit 99.1 Fresh2 Group Ltd. Completes Acquisition of SpeedIn INC, a Delivery Service Provider NEW YORK, July 28, 2023 /PRNewswire/ - Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES) (“Fresh2,” the “Company” or “we”), a company with operations in the United States and China focused on the business-to-business e-commerce and supply chain sectors for the restaurant su |
|
| July 28, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 (Address of principal executive office) Indicate by check mark whether the registrant |
|
| July 28, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 (Address of principal executive office) Indicate by check mark whether the registrant |
|
| July 27, 2023 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares par value US$0. |
|
| July 27, 2023 |
ANPC / AnPac Bio-Medical Science Co Ltd - ADR / Immensus LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Fresh2 Group Limited (Name of Issuer) Class A Ordinary Shares, par value US$0.01 (Title of Class of Securities) Class A Ordinary Shares: G0393E107 (CUSIP Number) Haohan Xu 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 646-409-6505 (Name, Address an |
|
| July 26, 2023 |
Exhibit 99.1 Fresh2 Group Ltd. Appoints New Chief Strategy Officer to Drive Advancement and Execution of Long-Term Growth Strategy NEW YORK, July 26, 2023 /PRNewswire/ - Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES) (“Fresh2,” the “Company” or “we”), a company with operations in the United States and China focused on the business-to-business e-commerce and supply c |
|
| July 26, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the regis |
|
| July 21, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the regis |
|
| July 21, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 (Address of principal executive office) Indicate by check mark whether the registrant |
|
| July 21, 2023 |
Exhibit 10.1 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 17 , 2023 by and among (1) Fresh2 Group Limited, an exempted company with limited liability incorporated under the laws of the British Virgin Islands (the “Fresh2”); (2) Immensus LLC, Zero2First Capital Limited, Future Capital Tech Pte. Ltd (Singapore), and River Hill China Ca |
|
| July 17, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 Fifth Avenue, Suite 2416 New York, NY 10019-6108 (Address of principal executive office) Indicate by check mark whether the registrant |
|
| July 7, 2023 |
AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT NASSAU ENTERPRISES LLC Exhibit 10.2 AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT FOR NASSAU ENTERPRISES LLC This Amended and Restated Limited Liability Company Agreement (hereinafter referred to as the "Agreement") is dated as of May 24th, 2023, by and among Foodbase Group Inc. and Haohan Xu (hereinafter referred to collectively as the "Members" and individually as a "Member") and Nassau Enterprises LLC, a D |
|
| July 7, 2023 |
Exhibit 10.1 INTEREST PURCHASE AGREEMENT THIS INTEREST PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of May 24th, 2023 by and among (1) Haohan Xu, as the selling member of Nassau Enterprises LLC (“Seller”); (2) Nassau Enterprises LLC, a company incorporated in Delaware (the “Company”); and (3) Foodbase Group Inc., a Delaware Corporation (the “Purchaser”) Each of the Purchaser, t |
|
| July 7, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the regis |
|
| June 15, 2023 |
Exhibit 10.1 SHARES PURCHASE AGREEMENT SHARES PURCHASE AGREEMENT (this “Agreement”), dated as of June 2, 2023, by and between Fresh2 Group Limited, a British Virgin Islands corporation (the “Company”), and Applegreen LLC (the “Investor”). A. The Company wishes to sell to the Investor, and the Investor wishes to purchase, on the terms and subject to the conditions set forth in this Agreement, ordin |
|
| June 15, 2023 |
6-K 1 ea180449-6kfresh2group.htm REPORT OF FOREIGN PRIVATE ISSUER U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of pr |
|
| June 15, 2023 |
WARRANT TO PURCHASE ORDINARY SHARES FRESH2 GROUP LIMITED Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| June 15, 2023 |
Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements NEW YORK, June 12, 2023 /PRNewswire/ - Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focu |
|
| June 15, 2023 |
Fresh2 Group Ltd. Announces US$4.4 Million Private Placement Exhibit 99.1 Fresh2 Group Ltd. Announces US$4.4 Million Private Placement NEW YORK, June 5, 2023 /PRNewswire/ - Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the |
|
| June 15, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the regis |
|
| May 22, 2023 |
Filed pursuant to Rule 424(b)(3) Registration Statement on Form F-6 Registration No. |
|
| May 17, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of principal executive office) Indicate by check mark whether the regist |
|
| May 16, 2023 |
6-K 1 ea178698-6kfresh2group.htm REPORT OF FOREIGN PRIVATE ISSUER U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39137 Fresh2 Group Limited 650 5TH AVE STE 2416 NEW YORK, NY 10019-6108 United States (Address of pri |
|
| May 16, 2023 |
Fresh2 Reports Fiscal Year 2022 Annual Financial Results Exhibit 99.1 Fresh2 Reports Fiscal Year 2022 Annual Financial Results NEW YORK, May 16, 2023 /PRNewswire/ — Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,“Fresh2,” the “Company” or “we”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce f |
|
| May 16, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement on Form F-3 (File No. 333-256630) and Form S-8 (File No 333-265413 and 333-259748) of Fresh2 Group Limited (f/k/a AnPac Bio-Medical Science Co., Ltd.) of our report dated May 16, 2022, which includes an explanatory paragraph as to the Company’s ab |
|
| May 16, 2023 |
Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022 Exhibit 99.3 Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022 NEW YORK, May 16, 2023 /PRNewswire — Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., “Fresh2,” the “Company” or “we”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerc |
|
| May 16, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officers Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Each of us, Haohan Xu and Chris Chang Yu, certify that: 1. I have reviewed this annual report on Form 20-F of Fresh2 Group Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make t |
|
| May 16, 2023 |
Fresh2 Reports First Quarter of Fiscal Year 2023 Financial Results Exhibit 99.2 Fresh2 Reports First Quarter of Fiscal Year 2023 Financial Results NEW YORK, May 16, 2023 /PRNewswire — Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., “Fresh2,” the “Company” or “we”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-c |
|
| May 16, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officers Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Each of us, Xiaoyu Li and Edwards Jinqiu Tang, certify that: 1. I have reviewed this annual report on Form 20-F of Fresh2 Group Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to m |
|
| May 16, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Fresh2 Group Limited (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of us, Haohan Xu and Chris Chang Yu, Co-Chief Executive Off |
|
| May 16, 2023 |
Exhibit 13.2 Certification by the Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Fresh2 Group Limited (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of us, Xiaoyu Li and Edwards Jinqiu Tang, Co-Chief Financia |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E |
|
| May 16, 2023 |
Exhibit 4.15 ANPAC BIO-MEDICAL SCIENCE CO., LTD. 2023 SHARE INCENTIVE PLAN Adopted on March 10, 2023 (the “Effective Date”) The purpose of the Amended and Restatement 2023 Share Incentive Plan (the “Plan”) is to promote the interests of AnPac Bio-Medical Science Co., Ltd. (the “Company”) and its shareholders by providing grantees with an appropriate incentive to encourage them to continue contribu |
|
| May 16, 2023 |
Independent Registered Public Accounting Firm’s Consent Exhibit 15.2 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of Fresh2 Group Ltd. (f/k/a AnPac Bio-Medical Science Co., Ltd.) on Form S-8 (File No. 333-265413 and 333-259748) and Form F-3 (File No. 333-256630) of our report dated May 16, 2023, which includes an explanatory paragraph as to the Company’s ability to co |
|
| May 10, 2023 |
Exhibit 3.1 |
|
| May 10, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39137 Fresh2 Group Limited 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal executive office) Indic |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| April 10, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal execut |
|
| April 10, 2023 |
AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc. Exhibit 99.1 AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc. New York, NY, April 3, 2023 /PRNewswire/- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and enterring into the operation of a business-to-business e-commerce food platform fo |
|
| April 10, 2023 |
6-K 1 ea176727-6kanpacbio.htm REPORT OF FOREIGN PRIVATE ISSUER U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323 |
|
| April 7, 2023 |
AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering Exhibit 99.1 AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering New York, NY, April 6, 2023 /PRNewswire/- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platf |
|
| April 7, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal execut |
|
| April 5, 2023 |
Securities Purchase Agreement, dated as of March 31, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 31, 2023, between AnPac Bio-Medical Science Co., Ltd., a company incorporated under the laws of the British Virgin Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “P |
|
| April 5, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address o |
|
| April 4, 2023 |
EX-10.3 7 ea176334ex10-3anpacbio.htm FORM OF PRE-FUNDED WARRANT Exhibit 10.3 [FORM OF CERTIFICATED WARRANT] PRE-FUNDED WARRANT TO PURCHASE CLASS A ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ANPAC BIO-MEDICAL SCIENCE CO., LTD. Warrant ADSs: Issue Date: THIS PRE-FUNDED WARRANT TO PURCHASE CLASS A ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, |
|
| April 4, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-256630 PROSPECTUS SUPPLEMENT (To Prospectus dated June 7, 2021) AnPac Bio-Medical Science Co., Ltd. 625,000 American Depositary Shares Pre-Funded Warrants to Purchase 125,000 American Depositary Shares Warrants to Purchase 750,000 American Depositary Shares 1,500,000 American Depositary Shares Underlying Warrants and Pre-Funded Warrants 37,500 |
|
| April 4, 2023 |
EX-10.2 6 ea176334ex10-2anpacbio.htm FORM OF WARRANT Exhibit 10.2 ANPAC BIO-MEDICAL SCIENCE CO., LTD. FORM OF AMERICAN DEPOSITARY SHARES PURCHASE WARRANT Date of Issuance: , 2023 (“Issuance Date”) AnPac Bio-Medical Science Co., Ltd., a British Virgin Islands corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby ackn |
|
| April 4, 2023 |
Placement Agency Agreement, dated as of March 31, 2023 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT March 31, 2023 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China Attention: Chris Chang Yu, Co-Chairman and Co-Chief Executive Officer Phone: +86-21-51085515 Dear Mr. Yu: This letter (the “Agreement”) constitutes the agreement by and between Univest Securities, LLC (“Univest” or |
|
| April 4, 2023 |
Securities Purchase Agreement, dated as of March 31, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 31, 2023, between AnPac Bio-Medical Science Co., Ltd., a company incorporated under the laws of the British Virgin Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “P |
|
| April 4, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal execut |
|
| April 4, 2023 |
Form of Placement Agent Warrant Exhibit 10.4 ANPAC BIO-MEDICAL SCIENCE CO., LTD. FORM OF PLACEMENT AGENT AMERICAN DEPOSITARY SHARES PURCHASE WARRANT Date of Issuance: , 2023 (“Issuance Date”) AnPac Bio-Medical Science Co., Ltd., a British Virgin Islands corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Univest Securities, LLC, th |
|
| April 3, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal execut |
|
| April 3, 2023 |
AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering Exhibit 99.1 AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering New York, NY, March 31, 2023 (GLOBE NEWSWIRE) - AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* AnPac Bio-Medical Science Co., Ltd. (Name of Issuer) Class A Ordinary Shares (Title of Class of Securities) 1411 Broadway FL16 New York NY Haohan Xu 001 646 409 6505 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communica |
|
| March 23, 2023 |
Exhibit 99.1 AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023 New York, NY, March 23, 2023 /PRNewswire/- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the oper |
|
| March 23, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co. |
|
| March 20, 2023 |
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the historical consolidated financial statements of our company for the six months ended June 30, 2021 and 2022, and the audited consolidated financial statements and accompa |
|
| March 20, 2023 |
Table of Contents Exhibit 99.1 ANPAC BIO-MEDICAL SCIENCE CO., LTD. INDEX TO UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Unaudited condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021 F-2 Unaudited condensed consolidated statements of operations and comprehensive loss for the six months ended June 30, 2022 and 2021 F-3 Unaudited condensed consolidated st |
|
| March 20, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal execut |
|
| March 7, 2023 |
Exhibit 99.1 COMPANY NO. 1563466 AnPac Bio-Medical Science Co., Ltd. (the “Company”) NOTICE OF CHANGE OF THE MAXIMUM NUMBER OF SHARES THE COMPANY IS AUTHORISED TO ISSUE pursuant to section 40 of the BVI Business Companies Act (As Revised) We hereby give notice that on the date hereof the Company has amended Clause 7 of its fifth amended and restated memorandum and articles of association to change |
|
| March 7, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 1411 Broadway FL16 New York NY (Address of principal executive office) Indicate by check mark whether the registrant files |
|
| March 6, 2023 |
AnPac Bio-Medical Science Announces US$5 Million Private Placement EX-99.1 2 tm238602d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AnPac Bio-Medical Science Announces US$5 Million Private Placement New York, NY, Mar. 6, 2023 (PRNewswire) - AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of |
|
| March 6, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal execut |
|
| February 15, 2023 |
Exhibit 99.1 AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider New York, NY, Feb. 15 2023 /PRNewswire/- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-t |
|
| February 15, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exe |
|
| February 13, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exe |
|
| February 13, 2023 |
Exhibit 99.1 AnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S. New York, NY, February 13, 2023 (GLOBE NEWSWIRE) - AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China announced that on February 13, 2023, the Company, through its subsidia |
|
| February 9, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exe |
|
| February 9, 2023 |
Exhibit 99.1 AnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce Platform Transaction expected to fuel the Company's growth in the U.S. food market New York, NY, February 9, 2023/PRNewswire/- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China focused on earl |
|
| January 27, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exec |
|
| January 27, 2023 |
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements Exhibit 99.1 AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements New York, NY, January 25, 2023 (GLOBE NEWSWIRE) - AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and a business-to-business food e-commerce company, |
|
| January 24, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exec |
|
| January 20, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exec |
|
| January 20, 2023 |
Letter of Friedman LLP to the U.S. Securities and Exchange Commission Dated January 18, 2023 EX-16.1 2 tm233972d2ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 January 18, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by AnPac Bio-Medical Science Co., Ltd. under Item 16.1 of its Form 6-K dated January 18, 2023. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disa |
|
| January 20, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exec |
|
| January 20, 2023 |
Exhibit 99.1 AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing New York, NY, January 20, 2023 (GLOBE NEWSWIRE) - AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on January 13, |
|
| December 29, 2022 |
6-K 1 tm2233596d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant’s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province |
|
| December 16, 2022 |
AnPac Bio Reports 48.8% Decrease in Net Loss in First Half of 2022 Exhibit 99.1 AnPac Bio Reports 48.8% Decrease in Net Loss in First Half of 2022 PHILADELPHIA, December 16, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the six months ended June 30, 2022. Financial highlights |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant’s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of |
|
| November 30, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exe |
|
| November 30, 2022 |
AnPac Announces regaining Compliance with Nasdaq Listing Requirement Exhibit 99.1 AnPac Announces regaining Compliance with Nasdaq Listing Requirement Philadelphia PA, November 30, 2022 – AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that the company has been notified by the Office of the Genera |
|
| November 10, 2022 |
AnPac Bio Announces Changes to the Board of Directors Exhibit 99.1 PRESS RELEASE AnPac Bio Announces Changes to the Board of Directors Philadelphia PA, November 10, 2022 ? AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (?AnPac Bio? or the ?Company?), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced the resignation of Yuyang Cui as (i) the Co-Chair of the board |
|
| November 10, 2022 |
6-K 1 tm2230233d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant’s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province |
|
| November 4, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exe |
|
| November 4, 2022 |
Exhibit 99.1 PRESS RELEASE AnPac Bio Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting $1 Bid Price Compliance Rule On or Before Nov. 23, 2022 Philadelphia, PA, November 4, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, |
|
| October 24, 2022 |
AnPac Bio-Medical Science Co., Ltd. Convertible Debenture March 16, 2021 Citibank, N.A. ? ADR Depositary 388 Greenwich Street New York, New York 10013 Re: ANPAC BIO-MEDICAL SCIENCE CO., LTD. ? Convertible Notes Due 2022 Ladies & Gentlemen, We refer to the Deposit Agreement, dated as of February 3, 2020, by and among Anpac Bio-Medical Science Co. Ltd. (the ?Company?), Citibank, N.A., as depositary (the ?Depositary?), and all Holders and Beneficial Owners |
|
| October 24, 2022 |
August 7, 2020 Citibank, N.A. ? ADR Depositary 388 Greenwich Street New York, New York 10013 Re: ANPAC BIO-MEDICAL SCIENCE CO., LTD. ? Convertible Notes Due 2021 Ladies & Gentlemen, We refer to the Deposit Agreement, dated as of February 3, 2020, by and among Anpac Bio-Medical Science Co. Ltd. (the ?Company?), Citibank, N.A., as depositary (the ?Depositary?), and all Holders and Beneficial Owners |
|
| October 24, 2022 |
EXECUTION COPY DEPOSIT AGREEMENT by and among ANPAC BIO-MEDICAL SCIENCE CO., LTD. and CITIBANK, N.A., as Depositary, and ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER February 3, 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 ?ADS Record Date? 1 Section 1.2 ?Affiliate? 1 Section 1.3 ?American Depositary Receipt(s)?, ?ADR(s)? and ?Receipt(s)? 1 Section |
|
| October 24, 2022 |
ANPAC BIO-MEDICAL SCIENCE CO., LTD. and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF FEBRUARY 3, 2020 Amendment No. 1 to the Deposit Agreement Dated as of [DATE] Table of Contents Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Effective Date 2 ARTICLE II AMEND |
|
| October 24, 2022 |
[Remaining of this page intentionally left in blank] July 23, 2021 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Re: ANPAC BIO-MEDICAL SCIENCE CO., LTD. ? Convertible Notes Due July 22, 2022 Ladies & Gentlemen: We refer to the Deposit Agreement, dated as of February 3, 2020, by and among Anpac Bio-Medical Science Co. Ltd. (the ?Company?), Citibank, N.A., as depositary (the ?Depositary?), and all Holders and Beneficial |
|
| October 24, 2022 |
CUSTODIAL SERVICES AGREEMENT FOR STRUCTURAL SAFEKEEPING ACCOUNT AT CITIBANK, N.A. ? NEW YORK BRANCH, AS CUSTODIAN, FOR ANPAC BIO-MEDICAL SCIENCE CO., LTD., AS CLIENT dated as of July 30, 2020 TABLE OF CONTENTS 1. DEFINITIONS 3 2. ESTABLISHMENT OF ACCOUNTS 4 3. REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS 5 4. INSTRUCTIONS 5 5. PERFORMANCE BY THE CUSTODIAN 6 6. ACCOUNT PROCEDURES - SECURITIES 7 7. |
|
| October 24, 2022 |
As filed with the Securities and Exchange Commission on October 24, 2022 Registration No. |
|
| October 24, 2022 |
and Citibank, N.A. NOTE CONVERSION ISSUANCE INSTRUCTION April 22, 2022 Citibank, N.A. ? ADR Depositary 388 Greenwich Street New York, New York 10013 Re: ANPAC BIO-MEDICAL SCIENCE CO., LTD. ? Convertible Debenture Due 2022 Ladies & Gentlemen, We refer to the Deposit Agreement, dated as of February 3, 2020, by and among Anpac Bio-Medical Science Co. Ltd. (the ?Company?), Citibank, N.A., as depositary (the ?Depositary?), and all Holders and Beneficial Own |
|
| October 18, 2022 |
6-K 1 tm2228384d16k.htm FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of |
|
| October 18, 2022 |
AnPac Bio Announces Plan to Implement ADS Ratio Change Exhibit 99.1 AnPac Bio Announces Plan to Implement ADS Ratio Change Philadelphia PA, October 18, 2022 ? AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (?AnPac Bio? or the ?Company?), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that it plans to change the ratio of the Company?s American Depositary Shares |
|
| October 17, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People’s Republic of China (Address of principal exec |
|
| October 17, 2022 |
Fifth Amended and Restated Memorandum and Articles of Association Exhibit 5.03 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES FIFTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF AnPac Bio-Medical Sciene Co., Ltd. Incorporated this 5th day of January 2010 Amended and Restated by meeting of the Shareholders on 8 June 2018 and further Amended and Restated on 27 January 2020 and further |
|
| October 12, 2022 |
ANPC / AnPac Bio-Medical Science Co., Ltd. / CRS Holdings Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 3)* AnPac Bio-Medical Science Co., Ltd. (Name of Issuer) Class A Ordinary Shares Class B Ordinary Shares (Title of Class of Securities) Class A Ordinary Shares: G0393E107 Class B Ordinary Shares: N/A (CUSIP Number) October 12, 2022 (Date of Event which Requ |
|
| October 3, 2022 |
AnPac Bio Announces Board and Management Changes Exhibit 99.1 AnPac Bio Announces Board and Management Changes Philadelphia PA, October 3, 2022 ? AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (?AnPac Bio? or the ?Company?), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced changes to its board composition and management team. Mr. Haohan Xu has been appoint |
|
| October 3, 2022 |
Fourth Amended and Restated Memorandum and Articles of Association Exhibit 5.03 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT (AS AMENDED) COMPANY LIMITED BY SHARES FOURTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF AnPac Bio-Medical Science Co., Ltd. Incorporated this 5th day of January 2010 Amended and Restated by meeting of the Shareholders on 8 June 2018 and further Amended and Restated on 27 January 2020 and furthe |
|
| October 3, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China (Address of principal exec |
|
| October 3, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China (Address of principal exec |
|
| September 27, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China (Address of principal ex |
|
| September 27, 2022 |
AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million Exhibit 99.1 PRESS RELEASE AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million Philadelphia, PA, September 26, 2022 ? AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that on September 26, 2022, the Company and |
|
| September 20, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China (Address of principal ex |
|
| September 20, 2022 |
AnPac Bio Appeals NASDAQ Delisting Notice; Hearing Granted and Scheduled for October 20, 2022 Exhibit 99.1 AnPac Bio Appeals NASDAQ Delisting Notice; Hearing Granted and Scheduled for October 20, 2022 Philadelphia, PA, September 19, 2022 ? AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that on September 16, 2022, the Company fil |
|
| September 13, 2022 |
Exhibit 99.1 AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Appeal PHILADELPHIA, Sept. 12, 2022 (GLOBE NEWSWIRE) - AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that on September 9 |
|
| September 13, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China (Address of principal ex |
|
| August 5, 2022 |
AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer Exhibit 99.1 PRESS RELEASE AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer Philadelphia, PA, August 5, 2022 ? AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of dir |
|
| August 5, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China (Address of principal execu |
|
| July 18, 2022 |
Exhibit 99.1 PRESS RELEASE AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees Philadelphia, PA, July 14, 2022 ? AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (ANPC), a biotechnology company with operations in the United States and China f |
|
| July 18, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China (Address of principal executi |
|
| June 29, 2022 |
ANPC / AnPac Bio-Medical Science Co., Ltd. / CRS Holdings Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 2)* AnPac Bio-Medical Science Co., Ltd. (Name of Issuer) Class A Ordinary Shares Class B Ordinary Shares (Title of Class of Securities) Class A Ordinary Shares: G0393E107 Class B Ordinary Shares: N/A (CUSIP Number) June 28, 2022 (Date of Event which Require |
|
| June 21, 2022 |
AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market Exhibit 99.1 PRESS RELEASE AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market Philadelphia, PA, June 10, 2022 ? AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that The Nasdaq Stock Market LLC (?Nasd |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant?s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of Chin |
|
| June 3, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 3, 2022 |
Exhibit 10.1 ANPAC BIO-MEDICAL SCIENCE CO., LTD. 2022 SHARE INCENTIVE PLAN Adopted on April 14 (the ?Effective Date?) 1. Purpose of the Plan The purpose of the Amended and Restatement 2022 Share Incentive Plan (the ?Plan?) is to promote the interests of AnPac Bio-Medical Science Co., Ltd. (the ?Company?) and its shareholders by providing grantees with an appropriate incentive to encourage them to |
|
| June 3, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) AnPac Bio-Medical Science Co. |
|
| May 31, 2022 |
AnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022 Exhibit 99.1 AnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022 PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) ? AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the first quarter ended March 31, 2022. The Company |
|
| May 31, 2022 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| May 31, 2022 |
Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| May 31, 2022 |
Exhibit 99.2 ANPAC BIO-MEDICAL SCIENCE CO., LTD. UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET (Amounts in thousands of U.S. dollars (?US$?), except for number of shares and per share data) March 31, 2022 Pro Forma Adjustments Note Reference As Adjusted May 31, 2022 US $ US $ (Unaudited) (Unaudited) ASSETS CURRENT ASSETS Cash and cash equivalents 73 4,400 (1 )(2)(4) 4,473 Advances to suppliers 1, |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant?s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China |
|
| May 31, 2022 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| May 31, 2022 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of May 27, 2022, by and between Anpac Bio-Medical Science Co., Ltd., a British Virgin Islands corporation (the ?Company?), and each buyer identified on the signature pages hereto (each, including its successors and assigns, a ?Buyer? and collectively, the ?Buyers?). WHEREAS: A. The Company an |
|
| May 26, 2022 |
Exhibit 10.2 PREFUNDED AMERICAN DEPOSITARY SHARES PURCHASE WARRANT AnPac Bio-Medical Science Co., Ltd. Warrant ADSs: Issue Date: May 16, 2022 THIS PREFUNDED AMERICAN DEPOSITARY SHARES PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Mr. Trung Tri Doan or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaf |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant?s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China |
|
| May 26, 2022 |
?Exhibit 10.1 SECURITIES PURCHASE AGREEMENT ? SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of May?16, 2022, by and between AnPac Bio-Medical Science Co.,?Ltd., a British Virgin Islands corporation (the ?Company?), and Mr.?Trung Tri Doan, an individual (the ?Investor?), with US Passport [???], residence at [???]. ? A.????????????The Company wishes to sell to the Investor, and the Inve |
|
| May 16, 2022 |
English version of Offset Agreement Exhibit 4.14 Offset Agreement Party A: Chris Chang Yu Party B: Anpac Bio-Medical Science Co., Ltd Party C: Anpac Bio-Medical Science (Lishui) Co., Ltd., a wholly owned subsidiary of Party B. Party D: CRS Holding Inc., which is wholly owned by Party A Pursuant to the ?Five-Party Agreement? effective 30 June 2021, as amended and restated, in the form attached hereto as Exhibit A, Party D has confirm |
|
| May 16, 2022 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ? In connection with the Annual Report of AnPac Bio-Medical Science Co., Ltd. (the ?Company?) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Edwards Jinqiu Tang, Chief Financial Officer |
|
| May 16, 2022 |
Consent of Independent Registered Accountant Firm (Friedman) Exhibit 15.1 ? ? CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ? We consent to the incorporation by reference in this Form S-8 Registration Statement, pertaining to the 2010 Share Incentive Plan, 2019 Share Incentive Plan, as amended, of AnPac Bio-Medical Science Co., Ltd., of our report dated May 16, 2022 relating to the consolidated balance sheet of AnPac Bio-Medical Science Co., Ltd. |
|
| May 16, 2022 |
Consent of Independent Registered Accountant Firm (Ernst & Young) Exhibit 15.3 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-238679) pertaining to the Employees? Savings Plan of AnPac Bio-Medical Science Co., Ltd. of our report dated May 15, 2020, with respect to the consolidated financial statements of AnPac Bio-Medical Science Co., Ltd. incorporated by refer |
|
| May 16, 2022 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ? I, Chris Chang Yu, certify that: ? 1. I have reviewed this annual report on Form 20-F of AnPac Bio-Medical Science Co., Ltd..; ? 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D. |
|
| May 16, 2022 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ? I, Edwards Jinqiu Tang, certify that: ? 1. I have reviewed this annual report on Form 20-F of AnPac Bio-Medical Science Co., Ltd.; ? 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make |
|
| May 16, 2022 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ? In connection with the Annual Report of AnPac Bio-Medical Science Co., Ltd. (the ?Company?) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Chris Chang Yu, Chief Executive Officer of th |
|
| May 16, 2022 |
Consent of Independent Registered Accountant Firm (Friedman) ? Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement on Form F-3 of Anpac Bio-Medical Science Co., Ltd. of our report dated May 16, 2022 with respect to the consolidated financial statements of Anpac Bio-Medical Science Co., Ltd. and subsidiaries included in its Annual Report on Form 20-F for the |
|
| May 16, 2022 |
English version of Five Party Agreement Exhibit 4.13 Five-Party Agreement Party A : Changwei System Technology (Shanghai) Co., Ltd AnPac Bio-Medical Technology (Lishui) Co., Ltd. (Hereinafter referred to as: domestic company) Party B: Anpac Bio-Medical Science Co., Ltd. (Hereinafter referred to as: overseas BVI company) Party C: CRS Holding Inc. (Registration Number: 1392174) (Hereinafter referred to as: Overseas CRS Company) Party D: C |
|
| May 11, 2022 |
EX-99.1 2 tm2215158d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AnPac Bio Regains Compliance with Market-Value-Of-Publicly Held Shares Requirement upon Transfer to The Nasdaq Capital Market Philadelphia, PA, May 11, 2022 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screeni |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant?s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant?s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant?s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of China |
|
| May 6, 2022 |
Exhibit 99.1 PRESS RELEASE Nasdaq Hearing Panel Grants AnPac Bio?s Request to Transfer Securities from The Nasdaq Global Market to The Nasdaq Capital Market Philadelphia, PA, May 6, 2022 ? AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K x Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: DECEMBER 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant?s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of Chi |
|
| April 21, 2022 |
EX-10.2 3 tm2213271d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 Investment Agreement (April 2, 2022) Party A is a Nasdaq publically traded company AnPac Bio-Medical Science Co., Ltd., along with its subsidiaries including AnPac Bio-Medical Science (Shanghai) Co., Ltd. (“AnPac Bio”), whose innovative product named Cancer Differentiation Analysis Technology (CDA) has been validated on hundreds of thousand |
|
| April 21, 2022 |
Investment Agreement by and between Chris Chang Yu and AnPac Bio-Medical Science Co., Ltd. Exhibit 10.3 Investment Agreement (April 7, 2022) Party A is a Nasdaq publically traded company AnPac Bio-Medical Science Co., Ltd., along with its subsidiaries including AnPac Bio-Medical Science (Shanghai) Co., Ltd. (?AnPac Bio?), whose innovative product named Cancer Differentiation Analysis Technology (CDA) has been validated on hundreds of thousands of samples, including multiple retrospectiv |
|
| April 21, 2022 |
Exhibit 10.1 Agreement of Investment Whereas AnPac Bio-Medical Science (Shanghai) Co., Ltd. (Party A, hereinafter referred to as ?Anpac Shanghai?, the registered address: No., 860, Fuping Road, Putuo District, Shanghai) is a subsidiary of the parent company called Anpac Bio-Medical Science Co., Ltd. (stock code: ANPC, hereinafter referred to as ?ANPC parent company?), with devotion in the developm |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39137 AnPac Bio-Medical Science Co., Ltd. (Registrant?s name) 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006 The People?s Republic of Chi |
|
| April 11, 2022 |
Offer Letter to Ms. Sheng Liu from AnPac Bio-Medical Science Co., Ltd. EX-10.2 3 tm2212455d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AnPac Bio-Medical Science Co., Ltd. April 6, 2022 Via Email Dear Ms. Sheng Liu ： This letter shall confirm our discussions pursuant to which you have indicated your willingness to serve as an independent director on the Board of Directors of AnPac Bio-Medical Science Co., Ltd. (the “Company”), Chairperson of the Nominating and Corporate Gov |
|
| April 11, 2022 |
Exhibit 10.1 Employment Agreement Party A: Legal Representative: Party B: Gender: Highest Education: Date of Birth: ID Number: Address: Contact Number: Starting work on: Term of the Agreement: In accordance with the Labor Contract Law of the People?s Republic of China[, Regulation of Shanghai Municipality on Labor Contract,] and relevant laws, regulations and rules, Party A and Party B agree to en |
|
| April 11, 2022 |
Exhibit 99.1 AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member Philadelphia, PA, April 8, 2022 ? AnPac Bio-Medical Science Co., Ltd. (?AnPac Bio,? the ?Company? or ?we?) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. |
